Evidence map›Paper›PMID 36591465›Full record

ArticleFrontiers in oncology2022

Establishment of triple-negative breast cancer cells based on BMI: A novel model in the correlation between obesity and breast cancer.

Daniela Shveid Gerson, Raquel Gerson-Cwilich, Cesar Octavio Lara Torres, Alberto Chousleb de Kalach, José Luis Ventura Gallegos, Luis Ernesto Badillo-Garcia, Juan Enrique Bargalló Rocha, Antonio Maffuz-Aziz, Ernesto Roberto Sánchez Forgach, Gerardo Castorena Roji and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Daniela Shveid GersonCancer Center, American British Cowdray (ABC) Medical Center, Mexico City, Mexico.
Raquel Gerson-CwilichCancer Center, American British Cowdray (ABC) Medical Center, Mexico City, Mexico.
Cesar Octavio Lara TorresPathology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, Mexico.
Alberto Chousleb de KalachExperimental Surgery Department, American British Cowdray (ABC) Medical Center, Mexico City, Mexico.
José Luis Ventura GallegosDepartment of Genomic Medicine and Environmental Toxicology, Institute of Biomedical Research, National Autonomous University of Mexico, Mexico City, Mexico.
Luis Ernesto Badillo-GarciaDepartment of Genomic Medicine and Environmental Toxicology, Institute of Biomedical Research, National Autonomous University of Mexico, Mexico City, Mexico.
Juan Enrique Bargalló RochaCancer Center, American British Cowdray (ABC) Medical Center, Mexico City, Mexico.
Antonio Maffuz-AzizCancer Center, American British Cowdray (ABC) Medical Center, Mexico City, Mexico.
Ernesto Roberto Sánchez ForgachCancer Center, American British Cowdray (ABC) Medical Center, Mexico City, Mexico.
Gerardo Castorena RojiCancer Center, American British Cowdray (ABC) Medical Center, Mexico City, Mexico.
Carlos D Robles VidalCancer Center, American British Cowdray (ABC) Medical Center, Mexico City, Mexico.
Ariana Vargas-CastilloBiochemistry Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, Mexico.
Nimbe TorresDepartment of Nutrition Physiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, Mexico.
Armando R TovarDepartment of Nutrition Physiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, Mexico.
Mariela Contreras JarquínDepartment of Genomic Medicine and Environmental Toxicology, Institute of Biomedical Research, National Autonomous University of Mexico, Mexico City, Mexico.
Jesús Tenahuatzin Gómez OsnayaDepartment of Genomic Medicine and Environmental Toxicology, Institute of Biomedical Research, National Autonomous University of Mexico, Mexico City, Mexico.
Alejandro Zentella-DehesaCancer Center, American British Cowdray (ABC) Medical Center, Mexico City, Mexico.
Centro Médico ABC · MXInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Obesity has been associated with an increased risk of biologically aggressive variants in breast cancer. Women with obesity often have tumors diagnosed at later stages of the disease, associated with a poorer prognosis and a different response to treatment. Human cell lines have been derived from specific subtypes of breast cancer and have served to define the cell physiology of corresponding breast cancer subtypes. However, there are no current cell lines for breast cancer specifically derived from patients with different BMIs. The availability of those breast cancer cell lines should allow to describe and unravel functional alterations linked to these comorbidities. Methods: Cell cultures were established from tumor explants. Once generated, the triple negative subtype in a patient with obesity and a patient with a normal BMI were chosen for comparison. For cellular characterization, the following assays were conducted: proliferation assays, chemo - sensitivity assays for doxorubicin and paclitaxel, wound healing motility assays, matrix invasion assays, breast cancer cell growth to estradiol by chronic exposure to leptin, induction of endothelial permeability and tumorigenic potential in athymic mice with normo - versus hypercaloric diets with an evaluation of the epithelium - mesenchymal transformation proteins. Results: Two different cell lines, were established from patients with breast cancer: DSG-BC1, with a BMI of 21.9 kg/m2 and DSG-BC2, with a BMI of 31.5 kg/m2. In vitro, these two cell lines show differential growth rates, motility, chemosensitivity, vascular permeability, response to leptin with an activation of the JAK2/STAT3/AKT signaling pathway. In vivo, they displayed distinct tumorigenic potential. In particular, DSG-BC2, presented higher tumorigenicity when implanted in mice fed with a hypercaloric diet. Discussion: To our knowledge, these primary cultures are the first in vitro representation of both breast cancer and obesity. DSG - BC2 presented a more aggressive in vivo and in vitro phenotype. These results support the hypothesis that breast cancer generated in an obese metabolic state may represent a contrasting variant within the same disease. This new model will allow both further comprehension, functional studies and the analysis of altered molecular mechanisms under the comorbidity of obesity and breast cancer.

Indexed as

BMI – body mass indexbreast cancercell culturecell linesleptin and endothelial activationobese adipose tissuestriple negative breast cancer

Identifiers

PMID36591465
PMCPMC9795201
OpenAlexW4311379842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.